- Home
- EOSE vs CELC Comparison
EOSE vs CELC Comparison
Compare EOSE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EOSE | CELC |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 430 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | EOSE | CELC |
|---|---|---|
| Price | $6.66 | $111.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $11.75 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 22.2M | 556.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $328.07 | N/A |
| Revenue Next Year | $100.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $7.58 |
| 52 Week High | $19.86 | $120.32 |
Technical Indicators
Market Signals| Indicator | EOSE | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 57.65 |
| Support Level | $4.90 | $97.75 |
| Resistance Level | $19.21 | $114.54 |
| Average True Range (ATR) | 0.88 | 4.99 |
| MACD | -0.48 | 0.34 |
| Stochastic Oscillator | 18.29 | 82.45 |
Price Performance
Historical ComparisonAbout EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.